It would have to be a HUGE offer for Imugene to sell. If the B-cell works then we control a paradigm shift in cancer treatment, we are sitting on a huge revenue earner. Imugene has already moved to control the space with the recent takeover of Mayo. The intellectual property we have is huge and continues to grow.
We may see partnerships but my feeling is Imugene will want to get maximum benefit from B-cell and take the products all the way to market( if B-cell works well)and start a production line of B cell cancer vaccines. If that happens then we will become a huge pharma in our own right long term.
Ann: Imugene doses first patient in HER-Vaxx phase 2 trial, page-31
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2275218 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 196677 | 3 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
